Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion is additionally listing 21,815 common shares on November 14, 2025, following the exercise of stock options by employees.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Additional Listing (Exercise of Stock Options)
- Class and Number of Shares: 21,815 registered common shares
- 167th Tranche: 7,109 shares
- 168th Tranche: 5,958 shares
- 169th Tranche: 1,155 shares
- 170th Tranche: 270 shares
- 171st Tranche: 3,650 shares
- 172nd Tranche: 3,673 shares
- Issue Price per Share (Par Value: KRW 1,000):
- 167th Tranche: KRW 79,311
- 168th Tranche: KRW 71,999
- 169th Tranche: KRW 156,285
- 170th Tranche: KRW 156,746
- 171st Tranche: KRW 123,606
- 172nd Tranche: KRW 128,858
- Capital Increase Method: Exercise of stock options
- Issue Date: October 27, 2025
- Dividend Record Date: January 1, 2025
- Listing Date: November 14, 2025
- Stock Code: Standard Code KR7068270008 (Short Code A068270)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Additional Listing Execution on Scheduled Date (November 14, 2025)
This disclosure details the additional listing of 21,815 common shares resulting from the exercise of stock options, making it important to confirm the completion of the listing on the scheduled date of November 14, 2025. Tracking the share issuance ensures verification of the increase in total issued shares. Updated total share counts and capital stock changes can be verified under ‘Total Number of Shares’ and ‘Changes in Capital Stock’ in upcoming periodic filings (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
